Galapagos (GLPG) announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific (TMO) for the decentralized manufacturing of Galapagos’ point-of-care CAR-T product candidate in the San Francisco area. Under the terms of the agreement, Thermo Fisher will provide GMP manufacturing as well as BioServices and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program in the San Francisco area, effective January 2024. Galapagos will initiate the technology transfer to enable Thermo Fisher’s manufacturing activities. This collaboration follows Galapagos’ agreement with Landmark Bio for decentralized CAR-T manufacturing in the Boston area announced in November 2023. Financial terms of the agreement are not disclosed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GLPG:
- BridGene in $27M collaboration and licensing pact with Galapagos
- Galapagos price target raised to $44 from $41 at BofA
- Galapagos signs agreement to transfer Jyseleca business to Alfasigma
- Galapagos to present new data at Ash 2023 fromongoing CD19 Car-t sudies
- Galapagos price target lowered by EUR 8 at JPMorgan